FIELD: biotechnology.
SUBSTANCE: humanized anti-HLA-A2 antibodies are proposed. CAR are also proposed, which include humanized anti-HLA-A2 antibodies. Modified cells including CAR, and methods for use of such modified cells for stimulation of immune tolerance in a subject are also proposed.
EFFECT: invention provides obtaining CAR with reduced cross reactivity to several allelic variants of HLA-A.
18 cl, 13 dwg, 9 tbl
Title | Year | Author | Number |
---|---|---|---|
NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
INTRODUCTION OF CONSTRUCTED T CELLS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCER | 2017 |
|
RU2757308C2 |
T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
Authors
Dates
2022-10-25—Published
2018-09-19—Filed